Vizgen

Cambridge, MA · Founded 2019 · Privately Held (backing)

Developer of biomolecule profiling technology designed to bring new insight into biological systems and disease. Vizgen is based in Cambridge, MA and was founded in 2019. Its last reported valuation was $380 million in Apr 2022. It has raised $184 million across 6 recorded rounds; the latest was a $47.8 million early-stage round in Dec 2025.

Last reported valuation
$379.7M
Oct 2026
Priced at
—
Total raised
$184.2M
Last round
Early Stage VC
Dec 2025

Vizgen key facts

as of Oct 2026
  • Developer of biomolecule profiling technology designed to bring new insight into biological systems and disease.
  • Vizgen is valued at approximately $379.7M as of Oct 2026 (last reported valuation).
  • It has raised $184.2M across 6 recorded rounds; the latest was Early Stage VC ($47.8M) in Dec 2025.
  • Notable investors include ARCH Venture Partners, M Ventures, Harvard University, Sofina, Tao Capital Partners — 10 tracked in total.
  • Vizgen has filed 5 Form Ds with the SEC since 2019, most recently Oct 2025 ($3.5M sold to 7 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$379.7M

Vizgen's last reported valuation, Apr 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Vizgen with a free account
  • ·Watch Vizgen: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Vizgen funding rounds

6 rounds
Dec 2025Early Stage VC$47.8MSEC filing▮
Oct 2025Debt$3.5MSEC filing▮
Oct 2024Later Stage VC$107.6MSEC filing▮
Apr 2022Later Stage VC$85.2MSEC filing▮
Mar 2021Early Stage VC$37.0MSEC filing▮

Vizgen valuation

Vizgen's last reported valuation was $380 million in Apr 2022. No priced round, secondary trade or fund mark has surfaced since.

How much has Vizgen raised?

Vizgen has raised $184 million across 6 recorded rounds since 2019. The largest was an $85.2 million later-stage round in Apr 2022; the most recent was a $47.8 million early-stage round in Dec 2025.

Vizgen has filed 5 Form Ds with the SEC since 2019, most recently in Oct 2025 ($3.5 million sold to 7 investors).

Vizgen investors

10 investors are on record for Vizgen, including ARCH Venture Partners, M Ventures, Harvard University and Sofina. By type, the record holds 3 venture capital firms, 1 hedge fund and 1 asset manager. The early-stage round in Dec 2025 drew 9 investors.

About Vizgen

Developer of biomolecule profiling technology designed to bring new insight into biological systems and disease. The company's technology focuses on unlocking the power of spatially resolved, single-cell gene expression profiling in intact tissue slices using spatial gene profiling measurements, enabling medical researchers to efficiently interrogate biology on a systems scale.

Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2019
Employees
130
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.